Impairment of Wound Healing in Patients with Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1480-1488

  Dangwal, Seema ^a   Stratmann, Bernd ^a   Bang, Claudia ^c   Lorenzen, Johan M ^b   Kumarswamy, Regalla ^a   Fiedler, Jan ^a   Falk, Christine S ^a,b   Scholz, Claus J ^d   Thum, Thomas ^a,b,e   Tschoepe, Diethelm ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IFB TX   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

diabetes mellitus, type 2; inflammation; microRNAs; peripheral arterial disease; wound healing; zonula occludens 1 protein

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICRORNA; MICRORNA 191; MICRORNA 200B; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN ZO1; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; MIRN191 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CELL MIGRATION; CHRONIC WOUND; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PARACRINE SIGNALING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN CELL; SKIN FIBROBLAST; THROMBOCYTE RELEASE REACTION; TISSUE REPAIR; WOUND HEALING IMPAIRMENT; AGED; BLOOD; CELL MOTION; DIABETIC ANGIOPATHY; METABOLISM; PROTEIN MICROARRAY; SECRETION (PROCESS); THROMBOCYTE; WOUND HEALING;

AGED; BLOOD PLATELETS; C-REACTIVE PROTEIN; CELL MOVEMENT; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; PROTEIN ARRAY ANALYSIS; WOUND HEALING;

EID: 84933050624     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.305048     Document Type: Article

References (35)

1. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366:1736-1743. doi: 10.1016/S0140-6736(05)67700-8.
2. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382-387.
3. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V, Curtin L, Engelgau M, Geiss L. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes care. 2004:27:1591-1597.
4. Peters EJ, Lavery LA; International Working Group on the Diabetic FOot. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care. 2001;24:1442-1447.
5. Siitonen OI, Niskanen LK, Laakso M, Siitonen JT, Pyörälä K. Lowerextremity amputations in diabetic and nondiabetic patients. A populationbased study in eastern Finland. Diabetes Care. 1993;16:16-20.
6. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-228. doi: 10.1001/jama.293.2.217.
7. Dinh T, Tecilazich F, Kafanas A, Doupis J, Gnardellis C, Leal E, Tellechea A, Pradhan L, Lyons TE, Giurini JM, Veves A. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61:2937-2947. doi: 10.2337/db12-0227.
8. Khaodhiar L, Dinh T, Schomacker KT, Panasyuk SV, Freeman JE, Lew R, Vo T, Panasyuk AA, Lima C, Giurini JM, Lyons TE, Veves A. The use of medical hyperspectral technology to evaluate microcirculatory changes in diabetic foot ulcers and to predict clinical outcomes. Diabetes Care. 2007;30:903-910. doi: 10.2337/dc06-2209.
9. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk. 1994;1:333-339.
10. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL Trial Participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-1934. doi: 10.1016/S0140-6736(05)67704-5.
11. Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP; DARTS/MEMO Collaboration. Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care. 2006;29:2252-2256. doi: 10.2337/dc06-0926.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233. doi: 10.1016/j.cell.2009.01.002.
13. Dangwal S, Thum T. microRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol. 2014;54:185-203. doi: 10.1146/annurev-pharmtox-011613-135957.
14. Dangwal S, Bang C, Thum T. Novel techniques and targets in cardiovascular microRNA research. Cardiovasc Res. 2012;93:545-554. doi: 10.1093/cvr/cvr297.
15. Fiedler J, Jazbutyte V, Kirchmaier BC, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124:720-730. doi: 10.1161/CIRCULATIONAHA.111.039008.
16. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-817. doi: 10.1161/CIRCRESAHA.110.226357.
17. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;3:1078. doi: 10.1038/ncomms2090.
18. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-684. doi: 10.1161/CIRCRESAHA.109.215566.
19. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kümpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2011;6:1540-1546. doi: 10.2215/CJN.00430111.
20. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is downregulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem. 2011;286:2047-2056. doi: 10.1074/jbc.M110.158790.
21. Chan YC, Roy S, Khanna S, Sen CK. Downregulation of endothelial microRNA-200b supports cutaneous wound angiogenesis by desilencing GATA binding protein 2 and vascular endothelial growth factor receptor. Arterioscler Thromb Vasc Biol. 2012;32:1372-1382. doi: 10.1161/ATVBAHA.112.248583.
22. Huo L, Wen W, Wang R, Kam C, Xia J, Feng W, Zhang M. Cdc42-dependent formation of the ZO-1/MRCK? complex at the leading edge controls cell migration. EMBO J. 2011;30:665-678. doi: 10.1038/emboj.2010.353.
23. Nagpal N, Kulshreshtha R. miR-191: an emerging player in disease biology. Front Genet. 2014;5:99. doi: 10.3389/fgene.2014.00099.
24. Kiezun A, Artzi S, Modai S, Volk N, Isakov O, Shomron N. miRviewer: a multispecies microRNA homologous viewer. BMC Res Notes. 2012;5:92. doi: 10.1186/1756-0500-5-92.
25. Gidlof O, van der Brug M, Ohman J, Gilje P, Olde B, Wahlestedt C, Erlinge D. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood. 2013:121:3908-3917, S1-26.
26. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013;112:595-600. doi: 10.1161/CIRCRESAHA.111.300539.
27. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009:2:ra81.
28. de Boer HC, van Solingen C, Prins J, Duijs JM, Huisman MV, Rabelink TJ, van Zonneveld AJ. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J. 2013;34:3451-3457. doi: 10.1093/eurheartj/eht007.
29. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436-2443. doi: 10.1093/eurheartj/eht149.
30. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:743-749. doi: 10.1016/j. jacc.2008.05.031.
31. Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T, Granada JF, Kleiman NS, Ballantyne CM, Lev EI. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008:156:1002.e1-1002.e7.
32. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3:484-488. doi: 10.1161/CIRCGENETICS.110.958363.
33. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14:249-256. doi: 10.1038/ncb2441.
34. Taliana L, Benezra M, Greenberg RS, Masur SK, Bernstein AM. ZO-1: lamellipodial localization in a corneal fibroblast wound model. Invest Ophthalmol Vis Sci. 2005;46:96-103. doi: 10.1167/iovs.04-0145.
35. Katsuno T, Umeda K, Matsui T, Hata M, Tamura A, Itoh M, Takeuchi K, Fujimori T, Nabeshima Y, Noda T, Tsukita S, Tsukita S. Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol Biol Cell. 2008;19:2465-2475. doi: 10.1091/mbc.E07-12-1215.